Millenium Pharmaceuticals About
Millenium Millennium Pharmaceuticals currently markets three
products, the cardiovascular drug INTEGRILIN®
(eptifibatide) Injection -- which prevents the aggregation of blood
platelets that, when allowed to form clots, can obstruct the flow of blood
through the coronary arteries. and the oncology drug VELCADE® (bortezomib)
co-marketed with Johnson and Johnson. Campath
(alemtuzumab injection) is indicated for the treatment of B-cell chronic lymphocytic
leukemia (B-CLL) in patients who have been treated with alkylating agents
and who have failed fludarabine therapy. The company also has a
significant number of investigational drugs at various stages of clinical and
preclinical development, as described in the R&D section of this website, and
played a significant role in bringing the oncology drug Campath® (alemtuzumab)
Injection to market. INTEGRILIN® (EPTIFIBATIDE) INJECTION
-- ST-segment elevation myocardial infarction (STEMI);Coronary artery bypass graft
(CABG) surgery VELCADE® (bortezomib)-- advanced non-small cell lung
cancer; non-Hodgkin's lymphoma; lung, breast, prostate and ovarian cancers and
non-Hodgkin's lymphoma MLN1202 --rheumatoid arthritis, multiple sclerosis
and potentially other inflammatory conditions More
on Millenium